(Corrects third paragraph of story published July 5 to remove reference to injunction against Sunovion.)
July 5 (Bloomberg) -- Sunovion Pharmaceuticals Inc.’s bronchitis and emphysema drug Brovana infringed Mylan Inc.’s patents, a judge ruled.
Sunovion also agreed not to raise any claims about the validity and enforceability of Mylan’s patents, U.S. District Judge John Koeltl said in an order dated July 1 in New York.
“The making, using, offering to sell and selling of Brovana has infringed” five Mylan patents, Koeltl said.
A unit of Canonsburg, Pennsylvania-based Mylan sued Sunovion’s predecessor company in 2007 to block the introduction of Brovana, which Mylan said infringed patents for a spray to open bronchial passages.
Sunovion, based in Marlborough, Massachusetts, is a unit of Osaka, Japan-based Dainippon Sumitomo Pharma Co.
The case is Dey v. Sepracor, 07-cv-02353, U.S. District Court, Southern District of New York (Manhattan).
To contact the reporter on this story: Don Jeffrey in New York at firstname.lastname@example.org
To contact the editor responsible for this story: Michael Hytha at email@example.com